A Qualitative Interview Study on Expanded Access Clinical Trials for Compassionate Use in Japan

References

• Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 2012;11(3):191–200. doi:10.1038/nrd3681
   PubMed Web of Science ®Google Scholar
• Nagai S. Flexible and expedited regulatory review processes for innovative medicines and regenerative medical products in the US, the EU, and Japan. Int J Mol Sci. 2019;20(15):3801. doi:10.3390/ijms20153801
   PubMed Web of Science ®Google Scholar
• Aliu P, Sarp S, Reichenbach R, et al. International country-level trends, factors, and disparities in compassionate use access to unlicensed products for patients with serious medical conditions. JAMA Health Forum. 2022;3(4):e220475. doi:10.1001/jamahealthforum.2022.0475
   Google Scholar
• Wu J, Yang Y, Yu J, Qiao L, Zuo W, Zhang B. Efficacy and safety of compassionate use for rare diseases: a scoping review from 1991 to 2022. Orphanet J Rare Dis. 2023;18(1):368. doi:10.1186/s13023-023-02978-x
   Web of Science ®Google Scholar
• Yen E, Davis JM, Milne CP. Impact of regulatory incentive programs on the future of pediatric drug development. Ther Innov Regul Sci. 2019;53(5):609–614. doi:10.1177/2168479019837522
   Web of Science ®Google Scholar
• Gerasimov E, Donoghue M, Bilenker J, Watt T, Goodman N, Laetsch TW. Before it’s too late: multistakeholder perspectives on compassionate access to investigational drugs for pediatric patients with cancer. Am Soc Clin Oncol Educ Book. 2020;40:1–10. doi:10.1200/EDBK_278995
   PubMedGoogle Scholar
• Flieger K. FDA finds new ways to speed treatment to patients. FDA Consum. 1993;27(8):14–18. PMID: 10129048.
   Google Scholar
• Jarow JP, Lurie P, Ikenberry SC, Lemery S. Overview of FDA’s expanded access program for investigational drugs. Ther Innov Regul Sci. 2017;51(2):177–179. doi:10.1177/2168479017694850
   PubMed Web of Science ®Google Scholar
• Puthumana J, Miller JE, Kim J, Ross JS. Availability of investigational medicines through the US Food and Drug Administration’s Expanded Access and compassionate use programs. JAMA Network Open. 2018;1(2):e180283. doi:10.1001/jamanetworkopen.2018.0283
   PubMed Web of Science ®Google Scholar
• Rahbari M, Rahbari NN. Compassionate use of medicinal products in Europe: current status and perspectives. Bull World Health Organ. 2011;89(3):163. PMID: 21379408; PMCID: PMC3044254. doi:10.2471/BLT.10.085712
   PubMed Web of Science ®Google Scholar
• Balasubramanian G, Morampudi S, Chhabra P, Gowda A, Zomorodi B. An overview of compassionate use programs in the European Union member states. Intractable Rare Dis Res. 2016;5(4):244–254. PMID: 27904819; PMCID: PMC5116859. doi:10.5582/irdr.2016.01054
   PubMedGoogle Scholar
• Ministry of Health, Labour and Welfare, Japan. Expanded access clinical trials from humanitarian perspective; 2016. in Japanese. Available from: https://www.mhlw.go.jp/web/t_doc?dataId=00tc1562&dataType=1&pageNo=1. Accessed October 4, 2021.
   Google Scholar
• Ministry of Health, Labour and Welfare, Japan. List of drugs and/or pharmaceutical companies requested for development due to high medical needs based on the results of review by the Investigational Committee on Medically Necessary Investigational New Drugs and Off-Label Use Drugs. in Japanese. Available from: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/iyakuhin/kaihatsuyousei/index.html. Accessed October 4, 2021.
   Google Scholar
• Maeda H, Uchida M, Kusano M, Tsukamoto K, Yamanoi M. Characteristics of the compassionate use program in Japan: an analysis of expanded access clinical trials from 2016 to 2021. Clin Pharmacol Ther. 2022;112(4):817–823. doi:10.1002/cpt.2641
   Web of Science ®Google Scholar
• Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349–357. doi:10.1093/intqhc/mzm042
   PubMed Web of Science ®Google Scholar
• Braun V, Clark V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77–101. doi:10.1191/1478088706qp063oa
   Google Scholar
• IQVIA Holdings, Inc. Japan Top Line Market Date FY2023; 2024. Available from: https://www.iqvia.com/-/media/iqvia/pdfs/japan/topline-market-data/2024/toplinedata_fy_2023.pdf. Accessed June 21, 2024.
   Google Scholar
• Nichols E; Institute of Medicine (US) Roundtable for the Development of Drugs and Vaccines Against AIDS. Expanding Access to Investigational Therapies for HIV Infection and AIDS: March 12–13, 1990 Conference Summary. Washington (DC): National Academies Press (US); 1991.
   Google Scholar
• McKee AE, Markon AO, Chan-Tack KM, Lurie P. How often are drugs made available under the Food and Drug Administration’s expanded access process approved? J Clin Pharmacol. 2017;57(Suppl 10):S136–S142. doi:10.1002/jcph.960
   Web of Science ®Google Scholar
• Tsuyuki K, Yano K, Watanabe N, Aruga A, Yamato M. Compassionate use of drugs and medical devices in the United States, the European Union, and Japan. Regen Ther. 2016;4:18–26. doi:10.1016/j.reth.2015.11.002
   Web of Science ®Google Scholar
• Nakada H, Folkers KM, Takashima K. Comparative assessment of non-trial access to investigational medical products in the US and Japan. Ther Innov Regul Sci. 2021;55(2):401–407. doi:10.1007/s43441-020-00228-x
   Web of Science ®Google Scholar
• Maeda H, Kurokawa T. Recent trends for drug lag in clinical development of oncology drugs in Japan: does the oncology drug lag still exist in Japan? Int J Clin Oncol. 2015;20(6):1072–1080. doi:10.1007/s10147-015-0825-4
   Web of Science ®Google Scholar
• Maeda H, Hara A, Ofuchi M, Shingai R, Misumi T, Murai Y. Trends in oncology drug lags in Japan from 2001 to 2020: a cross-sectional study. Clin Transl Sci. 2023;16(12):2665–2674. doi:10.1111/cts.13660
   Web of Science ®Google Scholar
• Tanaka M, Idei M, Sakaguchi H, et al. Achievements and challenges of the Sakigake designation system in Japan. Br J Clin Pharmacol. 2021;87(10):4027–4035. doi:10.1111/bcp.14807
   PubMed Web of Science ®Google Scholar
• Matsushita S, Tachibana K, Kusakabe T, Hirayama R, Tsutsumi Y, Kondoh M. Overview of the premarketing and postmarketing requirements for drugs granted Japanese conditional marketing approval. Clin Transl Sci. 2021;14(3):806–811. doi:10.1111/cts.12898
   PubMed Web of Science ®Google Scholar
• Maeda H, Fukuda Y, Uchida M. Assessment of drugs approved by public knowledge-based applications (Kouchi-shinsei) during the last two decades in Japan. Clin Pharmacol Ther. 2021;110(4):1127–1135. doi:10.1002/cpt.2332
   Web of Science ®Google Scholar
• Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020;382(24):2327–2336. doi:10.1056/NEJMoa2007016
   PubMed Web of Science ®Google Scholar
• Aliu P, Sarp S, Fitzsimmons P. Increasing use of compassionate use/managed access channels to obtain medicines for use in COVID-19. Clin Pharmacol Ther. 2021;110(1):26–28. doi:10.1002/cpt.2140
   Web of Science ®Google Scholar
• Kalil AC. Treating COVID-19-off-label drug use, compassionate use, and randomized clinical trials during pandemics. JAMA. 2020;323(19):1897–1898. doi:10.1001/jama.2020.4742
   PubMed Web of Science ®Google Scholar
• Margat A, Pétré B, David S, et al. Monitoring Surveys in the Context of Covid-19, published in Belgium and France, in the light of health democracy. Patient Prefer Adherence. 2023;17:1721–1728. doi:10.2147/PPA.S397679
   PubMed Web of Science ®Google Scholar